Peripheral Arterial Disease Clinical Trial
Official title:
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.
Status | Recruiting |
Enrollment | 244 |
Est. completion date | April 30, 2031 |
Est. primary completion date | April 30, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years at time of informed consent signature - Informed Consent Form (ICF) is signed by the subject - Subject can comply with protocol requirements, including follow-up - Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5) - Patient has de novo or restenotic lesion(s) found in the common and/or external iliac artery(ies) - Patient has: Unilateral or bilateral single or multiple lesions (>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length - Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm - Patient has a sufficient (<50% stenotic) common femoral artery and at least one sufficient (<50% stenotic) femoral artery (deep or superficial). - Patient has at least one sufficient (<50% stenotic) infrapopliteal run-off vessel. Exclusion Criteria: - Life expectancy <1 year - Patient is pregnant at time of informed consent. - Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin). - Patient has severe chronic renal insufficiency (serum creatinine level > 2.5mg/dL) and not undergoing hemodialysis. - Patient has evidence of a systemic infection. - Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use. - Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure). - Patient has previous stenting in the iliac arteries. - Patient has previous surgical bypass in the target limb. - Patient is currently participating in another investigative clinical study unless received written approval by the sponsor. - Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery. - Patient has an abdominal aortic artery lesion or aneurysm. - Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament. - Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery). - Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral / tibial revascularization). |
Country | Name | City | State |
---|---|---|---|
Germany | Krankenhaus der Barmherzigen Brüder | Regensburg | |
Netherlands | Rijnstate Hospital | Arnhem | |
New Zealand | Auckland City Hospital | Auckland | |
United States | The University of Texas Southwestern Medical Center | Dallas | Texas |
United States | North Suburban Medical Center | Denver | Colorado |
United States | Radiology and Imaging Specialists of Lakeland | Lakeland | Florida |
United States | Texas Tech University Health Science Center | Lubbock | Texas |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
W.L.Gore & Associates |
United States, Germany, Netherlands, New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Patency | Blood flow through the target lesion (no evidence of binary restenosis >50% or occlusion) without a Target Lesion Revascularization (TLR). | 1 year | |
Secondary | Technical success | Deployment of device with < 30% residual stenosis on final angiography. | at the procedure | |
Secondary | Acute procedural success | Binary assessment based on technical success and freedom from device or procedure-related serious adverse events (SAE) requiring intervention. | at the procedure | |
Secondary | Clinical success | Improvement from baseline of at least 1 Rutherford Category and freedom from device or procedure-related SAE requiring intervention. | Through 1 month | |
Secondary | Hemodynamic Status | Change in Ankle-brachial index (ABI)/toe-brachial index (TBI) as compared to baseline | Through 5 years | |
Secondary | Change in EQ-5D-5L | Change in EQ-5D-5L responses as compared to baseline. The EQ-5D-5L Questionnaire measures quality of life (QoL) over 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is measured over five levels from no problems to extreme problems. Scored on a 0 to 100 scale with 0 as the worst possible health and 100 is the best possible health. | Through 5 years | |
Secondary | Change in WIQ | Change in Walking Impairment Questionnaire (WIQ) responses as compared to baseline. The WIQ is a validated QoL measurement of walking abilities over 3 dimensions: distance, speed, and stair-climbing. Scored on a 0 to 100 scale with 0 as no degree of difficulty and 100 is the highest degree of difficulty. | Through 5 years | |
Secondary | Primary patency | Blood flow through the target lesion (no evidence of binary restenosis >50% or occlusion) without a Target Lesion Revascularization (TLR). | Through 5 years | |
Secondary | Freedom from binary restenosis | Freedom from binary restenosis. binary restenosis defined as evidence of >50% restenosis or occlusion of the target lesion(s) based on core lab adjudicated duplex ultrasound or angiography | Through 5 years | |
Secondary | Primary assisted patency | Blood flow maintained (no evidence of occlusion) through the target lesion with or without a Target Lesion Revascularization (TLR). | Through 5 years | |
Secondary | Secondary patency | Blood flow through the target lesion with or without a Target Lesion Revascularization (TLR). | Through 5 years | |
Secondary | Freedom from target lesion revascularization | Freedom from target lesion revascularization (TLR). TLR defined as endovascular or surgical intervention performed on the target lesion(s). | Through 5 years | |
Secondary | Cumulative reintervention rate | Rate of first and recurrent Target Lesion Revascularization (TLR). | Through 5 years | |
Secondary | Freedom from clinically driven target lesion revascularization | Freedom from clinically driven target lesion revascularization. Endovascular or surgical intervention performed on the target lesion(s) in response to recurrent symptoms (increase = 1 Rutherford Category). | Through 5 years | |
Secondary | Amputation-free survival | Binary assessment based on freedom from major amputation (target limb, amputation above the metatarsals) and all-cause mortality | Through 5 years | |
Secondary | Survival | Freedom from all-cause mortality | Through 5 years | |
Secondary | Change in Rutherford Category | Change in Rutherford Category as compared to baseline. Scaled from 0 to 6, with 0 as asymptotic and 6 as major tissue loss, extending above the transmetatarsal (TM) level, functional foot no longer salvageable. | Through 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |